Evidence map›Paper›PMID 40895297›Full record

ReviewFrontiers in cellular and infection microbiology2025

Silver nanoparticles as next-generation antimicrobial agents: mechanisms, challenges, and innovations against multidrug-resistant bacteria.

Hazim O Khalifa, Atef Oreiby, Temesgen Mohammed, Mohamed A A Abdelhamid, Essam Nageh Sholkamy, Hamada Hashem, Ragab M Fereig

Abstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Article
  2. Green Synthesis of Silver Nanoparticles fromMolecules (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hazim O KhalifaDepartment of Veterinary Medicine, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates.
Atef OreibyDepartment of Veterinary Medicine, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates.
Temesgen MohammedDepartment of Veterinary Medicine, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates.
Mohamed A A AbdelhamidBiology Department, Faculty of Education and Arts, Sohar University, Sohar, Oman.
Essam Nageh SholkamyDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Hamada HashemDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt.
Ragab M FereigDepartment of Veterinary Medicine, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The escalating prevalence of multidrug-resistant (MDR) bacteria presents a critical global health challenge, necessitating the urgent development of alternative antimicrobial strategies. Silver nanoparticles (AgNPs) have emerged as promising antimicrobial agents due to their broad-spectrum activity, unique physicochemical properties, and multiple mechanisms of bacterial inhibition. Their nanoscale size, high surface area-to-volume ratio, and ability to generate reactive oxygen species (ROS) make them highly effective against both Gram-positive and Gram-negative bacteria. AgNPs exert their antimicrobial effects through diverse mechanisms, including membrane disruption, protein and DNA interactions, enzymatic inhibition, and interference with bacterial metabolic pathways. Despite their potent antibacterial activity, concerns regarding bacterial adaptation, cytotoxicity, and non-specific interactions have prompted extensive research into innovative delivery systems to enhance AgNP efficacy while minimizing adverse effects. This review comprehensively explores the synthesis methods and physical properties of AgNPs, emphasizing their antimicrobial mechanisms and emerging resistance patterns. Additionally, we discuss advanced targeted delivery approaches, including surface functionalization, biopolymer encapsulation, liposomal carriers, and stimuli-responsive nanoplatforms, which enhance the stability, selectivity, and controlled release of AgNPs. These strategies not only improve AgNP bioavailability but also reduce host toxicity and prevent bacterial resistance development. Furthermore, we highlight future directions in AgNP-based antimicrobial therapy, such as combinatorial treatments with antibiotics, advanced nanostructure modifications, and the integration of AgNPs into wound dressings, coatings, and biomedical devices. By synthesizing recent advancements, this review underscores the transformative potential of AgNPs as next-generation antimicrobial agents to combat MDR bacterial infections. Addressing the current limitations and optimizing AgNP formulations will be crucial for their successful clinical translation and for mitigating the global antibiotic resistance crisis.

Indexed as

Anti-Bacterial AgentsBacteriaDrug Resistance, Multiple, BacterialMetal NanoparticlesSilverGram-Negative BacteriaHumansAnti-Bacterial AgentsSilverantibiotic resistanceantimicrobial mechanismscontrolled releasemultidrug resistancenanomedicinesilver nanoparticlestargeted delivery

Identifiers

PMID40895297
PMCPMC12390974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.